Abeona Therapeutics Inc vs United States Oil ETF — how do they compare? Abeona Therapeutics Inc trades at $7.37 (market cap $421.19M), while United States Oil ETF trades at $127.03. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, United States Oil ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | USO | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | — |
52-Week High | $7.45 | $152.96 |
52-Week Low | $4.17 | $66.17 |
Enterprise Value | $276.10M | — |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
USO is trading at $126.49, up 0.45% with bullish technical momentum as moving averages signal strength. The stock faces mixed sentiment amid ongoing Middle East supply disruptions and OPEC demand forecast revisions. Recent headlines highlight volatility from Hormuz tensions and shifting oil market dynamics.
Outlook remains volatile with supply risks supporting prices but demand concerns creating headwinds. Key resistance at $128-$132 and support at $123-$119 will dictate near-term direction. Geopolitical developments and inventory data remain critical catalysts for oil-linked equities.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →